RxDoctor Payments Data

Stephen Sherwin

Medical Oncology · San Francisco, CANPI 1437461431

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,752,097 of the $6,879,066 with a category attached, or 98.2%. 5 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 49.1% of the total. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,879,066in general payments, 2019–2025

Across 336 payments — averaging $20,473 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$3.4M
  • Biogen$2.7M
  • Exelixis Inc.$718K
  • AbbVie$33K
  • Verastem, Inc.$14K

What the payments were for

  • Consulting fees$6,752,09798%
  • Travel & lodging$85,1741%
  • Food & beverage$8,7570%
  • Other$33,0380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurocrine Biosciences, Inc.234$3,379,695
Biogen64$2,735,214
Exelixis Inc.29$717,505
AbbVie3$33,038
Verastem, Inc.6$13,614

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,879,066 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Other medical oncology in San Francisco

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →